{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:29:51Z","timestamp":1794346191771,"version":"4.9.0"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41582-025-01065-y","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T13:05:41Z","timestamp":1741007141000},"page":"204-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A global perspective on research advances and future challenges in Friedreich ataxia"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-8630","authenticated-orcid":false,"given":"Elisabetta","family":"Indelicato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin B.","family":"Delatycki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Marcondes C.","family":"Fran\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1657-7368","authenticated-orcid":false,"given":"Sylvia","family":"Boesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"1065_CR1","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1212\/WNL.54.12.2322","volume":"54","author":"M Labuda","year":"2000","unstructured":"Labuda, M. et al. Unique origin and specific ethnic distribution of the Friedreich ataxia GAA expansion. Neurology 54, 2322\u20132324 (2000).","journal-title":"Neurology"},{"key":"1065_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jnc.12215","volume":"126","author":"P Vankan","year":"2013","unstructured":"Vankan, P. Prevalence gradients of Friedreich\u2019s ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge. J. Neurochem. 126, 11\u201320 (2013).","journal-title":"J. Neurochem."},{"key":"1065_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jnc.12218","volume":"126","author":"AH Koeppen","year":"2013","unstructured":"Koeppen, A. H. Nikolaus Friedreich and degenerative atrophy of the dorsal columns of the spinal cord. J. Neurochem. 126, 4\u201310 (2013).","journal-title":"J. Neurochem."},{"key":"1065_CR4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.ajhg.2021.03.011","volume":"108","author":"C Depienne","year":"2021","unstructured":"Depienne, C. & Mandel, J. L. 30 years of repeat expansion disorders: what have we learned and what are the remaining challenges? Am. J. Hum. Genet. 108, 764\u2013785 (2021).","journal-title":"Am. J. Hum. Genet."},{"key":"1065_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/iub.2597","volume":"74","author":"N Maio","year":"2022","unstructured":"Maio, N. & Rouault, T. A. Mammalian iron sulfur cluster biogenesis and human diseases. IUBMB Life 74, 705 (2022).","journal-title":"IUBMB Life"},{"key":"1065_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41582-024-00957-9","volume":"20","author":"S Boesch","year":"2024","unstructured":"Boesch, S. & Indelicato, E. Approval of omaveloxolone for Friedreich ataxia. Nat. Rev. Neurol. 20, 313\u2013314 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"1065_CR7","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","volume":"271","author":"V Campuzano","year":"1996","unstructured":"Campuzano, V. et al. Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423\u20131427 (1996).","journal-title":"Science"},{"key":"1065_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nature01596","volume":"422","author":"A Savellev","year":"2003","unstructured":"Savellev, A., Everett, C., Sharpe, T., Webster, Z. & Festenstein, R. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 422, 909\u2013913 (2003).","journal-title":"Nature"},{"key":"1065_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nchembio815","volume":"2","author":"D Herman","year":"2006","unstructured":"Herman, D. et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich\u2019s ataxia. Nat. Chem. Biol. 2, 551\u2013558 (2006).","journal-title":"Nat. Chem. Biol."},{"key":"1065_CR10","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1093\/hmg\/ddaa267","volume":"29","author":"LN Rodden","year":"2020","unstructured":"Rodden, L. N. et al. Methylated and unmethylated epialleles support variegated epigenetic silencing in Friedreich ataxia. Hum. Mol. Genet. 29, 3818\u20133829 (2020).","journal-title":"Hum. Mol. Genet."},{"key":"1065_CR11","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","volume":"6","author":"V Campuzano","year":"1997","unstructured":"Campuzano, V. et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. 6, 1771\u20131780 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"1065_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/ana.24595","volume":"79","author":"CA Galea","year":"2016","unstructured":"Galea, C. A. et al. Compound heterozygous FXN mutations and clinical outcome in Friedreich ataxia. Ann. Neurol. 79, 485\u2013495 (2016).","journal-title":"Ann. Neurol."},{"key":"1065_CR13","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/acn3.52027","volume":"11","author":"MM Shen","year":"2024","unstructured":"Shen, M. M., Rummey, C. & Lynch, D. R. Phenotypic variation of FXN compound heterozygotes in a Friedreich ataxia cohort. Ann. Clin. Transl. Neurol. 11, 1110\u20131121 (2024).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1065_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10048-019-00594-1","volume":"21","author":"A Candayan","year":"2020","unstructured":"Candayan, A. et al. The first biallelic missense mutation in the FXN gene in a consanguineous Turkish family with Charcot-Marie-Tooth-like phenotype. Neurogenetics 21, 73\u201378 (2020).","journal-title":"Neurogenetics"},{"key":"1065_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/hmg\/9.8.1219","volume":"9","author":"M Coss\u00e9e","year":"2000","unstructured":"Coss\u00e9e, M. et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum. Mol. Genet. 9, 1219\u20131226 (2000).","journal-title":"Hum. Mol. Genet."},{"key":"1065_CR16","doi-asserted-by":"publisher","first-page":"E1499","DOI":"10.1212\/WNL.0000000000200913","volume":"99","author":"C Rummey","year":"2022","unstructured":"Rummey, C. et al. Natural history of Friedreich ataxia: heterogeneity of neurologic progression and consequences for clinical trial design. Neurology 99, E1499\u2013E1510 (2022).","journal-title":"Neurology"},{"key":"1065_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01475-9","volume":"15","author":"E Indelicato","year":"2020","unstructured":"Indelicato, E. et al. Onset features and time to diagnosis in Friedreich\u2019s ataxia. Orphanet J. Rare Dis. 15, 198 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"1065_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/jnc.12317","volume":"126","author":"MH Parkinson","year":"2013","unstructured":"Parkinson, M. H., Boesch, S., Nachbauer, W., Mariotti, C. & Giunti, P. Clinical features of Friedreich\u2019s ataxia: classical and atypical phenotypes. J. Neurochem. 126, 103\u2013117 (2013).","journal-title":"J. Neurochem."},{"key":"1065_CR19","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1093\/brain\/awm323","volume":"131","author":"MC Fahey","year":"2008","unstructured":"Fahey, M. C. et al. Vestibular, saccadic and fixation abnormalities in genetically confirmed Friedreich ataxia. Brain 131, 1035\u20131045 (2008).","journal-title":"Brain"},{"key":"1065_CR20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/BF00867423","volume":"242","author":"S Spicker","year":"1995","unstructured":"Spicker, S. et al. Fixation instability and oculomotor abnormalities in Friedreich\u2019s ataxia. J. Neurol. 242, 517\u2013521 (1995).","journal-title":"J. Neurol."},{"key":"1065_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000638","volume":"7","author":"M Patel","year":"2021","unstructured":"Patel, M. et al. Body mass index and height in the Friedreich Ataxia Clinical Outcome Measures Study. Neurol. Genet. 7, e638 (2021).","journal-title":"Neurol. Genet."},{"key":"1065_CR22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jspd.2019.02.005","volume":"7","author":"AL Simon","year":"2019","unstructured":"Simon, A. L. et al. Scoliosis in patients with Friedreich ataxia: results of a consecutive prospective series. Spine Deform. 7, 812\u2013821 (2019).","journal-title":"Spine Deform."},{"key":"1065_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/BF00571511","volume":"89","author":"TR Helliwell","year":"1995","unstructured":"Helliwell, T. R. et al. The pathology of the lower leg muscles in pure forefoot pes cavus. Acta Neuropathol. 89, 552\u2013559 (1995).","journal-title":"Acta Neuropathol."},{"key":"1065_CR24","doi-asserted-by":"publisher","first-page":"109828","DOI":"10.1016\/j.diabres.2022.109828","volume":"186","author":"J Tamaroff","year":"2022","unstructured":"Tamaroff, J. et al. Friedreich\u2019s ataxia related diabetes: epidemiology and management practices. Diabetes Res. Clin. Pract. 186, 109828 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1065_CR25","doi-asserted-by":"publisher","first-page":"6831","DOI":"10.1007\/s10072-022-06360-w","volume":"43","author":"M Fichera","year":"2022","unstructured":"Fichera, M. et al. Comorbidities in Friedreich ataxia: incidence and manifestations from early to advanced disease stages. Neurol. Sci. 43, 6831\u20136838 (2022).","journal-title":"Neurol. Sci."},{"key":"1065_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/jnc.12216","volume":"126","author":"M Cnop","year":"2013","unstructured":"Cnop, M., Mulder, H. & Igoillo-Esteve, M. Diabetes in Friedreich ataxia. J. Neurochem. 126, 94\u2013102 (2013).","journal-title":"J. Neurochem."},{"key":"1065_CR27","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJM199610173351601","volume":"335","author":"A D\u00fcrr","year":"1996","unstructured":"D\u00fcrr, A. et al. Clinical and genetic abnormalities in patients with Friedreich\u2019s ataxia. N. Engl. J. Med. 335, 1169\u20131175 (1996).","journal-title":"N. Engl. J. Med."},{"key":"1065_CR28","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1474-4422(14)70321-7","volume":"14","author":"K Reetz","year":"2015","unstructured":"Reetz, K. et al. Biological and clinical characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 14, 174\u2013182 (2015).","journal-title":"Lancet Neurol."},{"key":"1065_CR29","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/acn3.332","volume":"3","author":"M Patel","year":"2016","unstructured":"Patel, M. et al. Progression of Friedreich ataxia: quantitative characterization over 5 years. Ann. Clin. Transl. Neurol. 3, 684\u2013694 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1065_CR30","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S1474-4422(16)30287-3","volume":"15","author":"K Reetz","year":"2016","unstructured":"Reetz, K. et al. Progression characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurol. 15, 1346\u20131354 (2016).","journal-title":"Lancet Neurol."},{"key":"1065_CR31","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.eclinm.2019.11.006","volume":"18","author":"C Rummey","year":"2020","unstructured":"Rummey, C., Farmer, J. M. & Lynch, D. R. Predictors of loss of ambulation in Friedreich\u2019s ataxia. EClinicalMedicine 18, 100213 (2020).","journal-title":"EClinicalMedicine"},{"key":"1065_CR32","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/ana.20333","volume":"56","author":"R Sharma","year":"2004","unstructured":"Sharma, R. et al. Friedreich ataxia in carriers of unstable borderline GAA triplet-repeat alleles. Ann. Neurol. 56, 898\u2013901 (2004).","journal-title":"Ann. Neurol."},{"key":"1065_CR33","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1212\/WNL.49.6.1617","volume":"49","author":"M Ragno","year":"1997","unstructured":"Ragno, M. et al. Broadened Friedreich\u2019s ataxia phenotype after gene cloning: minimal GAA expansion causes late-onset spastic ataxia. Neurology 49, 1617\u20131620 (1997).","journal-title":"Neurology"},{"key":"1065_CR34","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.29687","volume":"39","author":"E Indelicato","year":"2024","unstructured":"Indelicato, E. et al. Predictors of survival in Friedreich\u2019s ataxia: a prospective cohort study. Mov. Disord. 39, 510\u2013518 (2024).","journal-title":"Mov. Disord."},{"key":"1065_CR35","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s004390050458","volume":"99","author":"C Epplen","year":"1997","unstructured":"Epplen, C. et al. Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene. Hum. Genet. 99, 834\u2013836 (1997).","journal-title":"Hum. Genet."},{"key":"1065_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jns.2015.03.024","volume":"352","author":"G Tai","year":"2015","unstructured":"Tai, G., Yiu, E. M., Corben, L. A. & Delatycki, M. B. A longitudinal study of the Friedreich ataxia impact scale. J. Neurol. Sci. 352, 53\u201357 (2015).","journal-title":"J. Neurol. Sci."},{"key":"1065_CR37","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ejpn.2019.08.004","volume":"23","author":"R Brandsma","year":"2019","unstructured":"Brandsma, R. et al. A clinical diagnostic algorithm for early onset cerebellar ataxia. Eur. J. Paediatr. Neurol. 23, 692\u2013706 (2019).","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"1065_CR38","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/ene.12341","volume":"21","author":"BPC Van de Warrenburg","year":"2014","unstructured":"Van de Warrenburg, B. P. C. et al. EFNS\/ENS consensus on the diagnosis and management of chronic ataxias in adulthood. Eur. J. Neurol. 21, 552\u2013562 (2014).","journal-title":"Eur. J. Neurol."},{"key":"1065_CR39","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1007\/s00415-023-11745-8","volume":"270","author":"Z Fleszar","year":"2023","unstructured":"Fleszar, Z. et al. Short-read genome sequencing allows \u2018en route\u2019 diagnosis of patients with atypical Friedreich ataxia. J. Neurol. 270, 4112\u20134117 (2023).","journal-title":"J. Neurol."},{"key":"1065_CR40","doi-asserted-by":"publisher","first-page":"fcad020","DOI":"10.1093\/braincomms\/fcad020","volume":"5","author":"B Uppili","year":"2023","unstructured":"Uppili, B. et al. Sequencing through hyperexpanded Friedreich\u2019s ataxia-GAA repeats by nanopore technology: implications in genotype-phenotype correlation. Brain Commun. 5, fcad020 (2023).","journal-title":"Brain Commun."},{"key":"1065_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1086\/301680","volume":"62","author":"SI Bidichandani","year":"1998","unstructured":"Bidichandani, S. I., Ashizawa, T. & Patel, P. I. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am. J. Hum. Genet. 62, 111\u2013121 (1998).","journal-title":"Am. J. Hum. Genet."},{"key":"1065_CR42","doi-asserted-by":"publisher","first-page":"14588","DOI":"10.1074\/jbc.273.23.14588","volume":"273","author":"K Ohshima","year":"1998","unstructured":"Ohshima, K., Montermini, L., Wells, R. D. & Pandolfo, M. Inhibitory effects of expanded GAA\u00b7TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J. Biol. Chem. 273, 14588\u201314595 (1998).","journal-title":"J. Biol. Chem."},{"key":"1065_CR43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1097-2765(00)80474-8","volume":"3","author":"N Sakamoto","year":"1999","unstructured":"Sakamoto, N. et al. Sticky DNA: self-association properties of long GAA.TTC repeats in R.R.Y triplex structures from Friedreich\u2019s ataxia. Mol. Cell 3, 465\u2013475 (1999).","journal-title":"Mol. Cell"},{"key":"1065_CR44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/ana.24260","volume":"76","author":"E Soragni","year":"2014","unstructured":"Soragni, E. et al. Epigenetic therapy for Friedreich ataxia. Ann. Neurol. 76, 489\u2013508 (2014).","journal-title":"Ann. Neurol."},{"key":"1065_CR45","doi-asserted-by":"publisher","first-page":"41469","DOI":"10.1074\/jbc.M006539200","volume":"275","author":"P Cavadini","year":"2000","unstructured":"Cavadini, P., Adamec, J., Taroni, F., Gakh, O. & Isaya, G. Two-step processing of human frataxin by mitochondrial processing peptidase. Precursor and intermediate forms are cleaved at different rates. J. Biol. Chem. 275, 41469\u201341475 (2000).","journal-title":"J. Biol. Chem."},{"key":"1065_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016199","volume":"6","author":"S Schmucker","year":"2011","unstructured":"Schmucker, S. et al. Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU\/NFS1\/ISD11 iron-sulfur assembly complex. PLoS ONE 6, e16199 (2011).","journal-title":"PLoS ONE"},{"key":"1065_CR47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jnc.12220","volume":"126","author":"A Pastore","year":"2013","unstructured":"Pastore, A. & Puccio, H. Frataxin: a protein in search for a function. J. Neurochem. 126, 43\u201352 (2013).","journal-title":"J. Neurochem."},{"key":"1065_CR48","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1126\/science.276.5319.1709","volume":"276","author":"M Babcock","year":"1997","unstructured":"Babcock, M. et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276, 1709\u20131712 (1997).","journal-title":"Science"},{"key":"1065_CR49","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.1021\/ja027967i","volume":"125","author":"T Yoon","year":"2003","unstructured":"Yoon, T. & Cowan, J. A. Iron-sulfur cluster biosynthesis. Characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. J. Am. Chem. Soc. 125, 6078\u20136084 (2003).","journal-title":"J. Am. Chem. Soc."},{"key":"1065_CR50","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1086\/303056","volume":"67","author":"J Adamec","year":"2000","unstructured":"Adamec, J. et al. Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia. Am. J. Hum. Genet. 67, 549\u2013562 (2000).","journal-title":"Am. J. Hum. Genet."},{"key":"1065_CR51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/ng1097-215","volume":"17","author":"A Rotig","year":"1997","unstructured":"Rotig, A. et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 17, 215\u2013217 (1997).","journal-title":"Nat. Genet."},{"key":"1065_CR52","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.tig.2008.05.008","volume":"24","author":"TA Rouault","year":"2008","unstructured":"Rouault, T. A. & Tong, W. H. Iron-sulfur cluster biogenesis and human disease. Trends Genet. 24, 398\u2013407 (2008).","journal-title":"Trends Genet."},{"key":"1065_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09989-y","volume":"10","author":"NG Fox","year":"2019","unstructured":"Fox, N. G. et al. Structure of the human frataxin-bound iron-sulfur cluster assembly complex provides insight into its activation mechanism. Nat. Commun. 10, 2210 (2019).","journal-title":"Nat. Commun."},{"key":"1065_CR54","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1038\/s41467-024-47310-8","volume":"15","author":"V Schulz","year":"2024","unstructured":"Schulz, V. et al. Mechanism and structural dynamics of sulfur transfer during de novo [2Fe-2S] cluster assembly on ISCU2. Nat. Commun. 15, 3269 (2024).","journal-title":"Nat. Commun."},{"key":"1065_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11470-9","volume":"10","author":"S Gervason","year":"2019","unstructured":"Gervason, S. et al. Physiologically relevant reconstitution of iron-sulfur cluster biosynthesis uncovers persulfide-processing functions of ferredoxin-2 and frataxin. Nat. Commun. 10, 3566 (2019).","journal-title":"Nat. Commun."},{"key":"1065_CR56","doi-asserted-by":"publisher","first-page":"101570","DOI":"10.1016\/j.jbc.2022.101570","volume":"298","author":"MA Uzarska","year":"2022","unstructured":"Uzarska, M. A. et al. During FeS cluster biogenesis, ferredoxin and frataxin use overlapping binding sites on yeast cysteine desulfurase Nfs1. J. Biol. Chem. 298, 101570 (2022).","journal-title":"J. Biol. Chem."},{"key":"1065_CR57","doi-asserted-by":"publisher","first-page":"10559","DOI":"10.1038\/s41467-024-54585-4","volume":"15","author":"R Steinhilper","year":"2024","unstructured":"Steinhilper, R. et al. Two-stage binding of mitochondrial ferredoxin-2 to the core iron-sulfur cluster assembly complex. Nat. Commun. 15, 10559 (2024).","journal-title":"Nat. Commun."},{"key":"1065_CR58","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.omtm.2020.08.018","volume":"19","author":"B Belbellaa","year":"2020","unstructured":"Belbellaa, B., Reutenauer, L., Messaddeq, N., Monassier, L. & Puccio, H. High levels of frataxin overexpression lead to mitochondrial and cardiac toxicity in mouse models. Mol. Ther. Methods Clin. Dev. 19, 120\u2013138 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1065_CR59","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.omtm.2022.02.002","volume":"24","author":"C Huichalaf","year":"2022","unstructured":"Huichalaf, C. et al. In vivo overexpression of frataxin causes toxicity mediated by iron-sulfur cluster deficiency. Mol. Ther. Methods Clin. Dev. 24, 367\u2013378 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1065_CR60","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.cell.2019.03.045","volume":"177","author":"T Ast","year":"2019","unstructured":"Ast, T. et al. Hypoxia rescues frataxin loss by restoring iron sulfur cluster biogenesis. Cell 177, 1507\u20131521.e16 (2019).","journal-title":"Cell"},{"key":"1065_CR61","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/84818","volume":"27","author":"H Puccio","year":"2001","unstructured":"Puccio, H. et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 27, 181\u2013186 (2001).","journal-title":"Nat. Genet."},{"key":"1065_CR62","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/jnc.12303","volume":"126","author":"P Gonz\u00e1lez-Cabo","year":"2013","unstructured":"Gonz\u00e1lez-Cabo, P. & Palau, F. Mitochondrial pathophysiology in Friedreich\u2019s ataxia. J. Neurochem. 126, 53\u201364 (2013).","journal-title":"J. Neurochem."},{"key":"1065_CR63","doi-asserted-by":"publisher","first-page":"11492","DOI":"10.1073\/pnas.96.20.11492","volume":"96","author":"R Lodi","year":"1999","unstructured":"Lodi, R. et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc. Natl Acad. Sci. USA 96, 11492\u201311495 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1065_CR64","doi-asserted-by":"publisher","first-page":"1289027","DOI":"10.3389\/fnins.2023.1289027","volume":"17","author":"E Indelicato","year":"2023","unstructured":"Indelicato, E. et al. Skeletal muscle proteome analysis underpins multifaceted mitochondrial dysfunction in Friedreich\u2019s ataxia. Front. Neurosci. 17, 1289027 (2023).","journal-title":"Front. Neurosci."},{"key":"1065_CR65","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1093\/hmg\/ddad051","volume":"32","author":"E Indelicato","year":"2023","unstructured":"Indelicato, E. et al. Skeletal muscle transcriptomics dissects the pathogenesis of Friedreich\u2019s ataxia. Hum. Mol. Genet. 32, 2241\u20132250 (2023).","journal-title":"Hum. Mol. Genet."},{"key":"1065_CR66","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1093\/brain\/awy172","volume":"141","author":"J Gurgel-Giannetti","year":"2018","unstructured":"Gurgel-Giannetti, J. et al. A novel complex neurological phenotype due to a homozygous mutation in FDX2. Brain 141, 2289\u20132298 (2018).","journal-title":"Brain"},{"key":"1065_CR67","doi-asserted-by":"publisher","first-page":"40119","DOI":"10.1074\/jbc.M112.418889","volume":"287","author":"DR Crooks","year":"2012","unstructured":"Crooks, D. R. et al. Tissue specificity of a human mitochondrial disease: differentiation-enhanced mis-splicing of the Fe-S scaffold gene ISCU renders patient cells more sensitive to oxidative stress in ISCU myopathy. J. Biol. Chem. 287, 40119\u201340130 (2012).","journal-title":"J. Biol. Chem."},{"key":"1065_CR68","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"1065_CR69","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1177\/0883073812453498","volume":"27","author":"DR Lynch","year":"2012","unstructured":"Lynch, D. R., Deutsch, E. C., Wilson, R. B. & Tennekoon, G. Unanswered questions in Friedreich ataxia. J. Child. Neurol. 27, 1223\u20131229 (2012).","journal-title":"J. Child. Neurol."},{"key":"1065_CR70","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ana.21052","volume":"61","author":"I De Biase","year":"2007","unstructured":"De Biase, I. et al. Progressive GAA expansions in dorsal root ganglia of Friedreich\u2019s ataxia patients. Ann. Neurol. 61, 55\u201360 (2007).","journal-title":"Ann. Neurol."},{"key":"1065_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189990","volume":"12","author":"A Long","year":"2017","unstructured":"Long, A. et al. Somatic instability of the expanded GAA repeats in Friedreich\u2019s ataxia. PLoS One 12, e0189990 (2017).","journal-title":"PLoS One"},{"key":"1065_CR72","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/jnen\/nlx087","volume":"76","author":"AH Koeppen","year":"2017","unstructured":"Koeppen, A. H., Becker, A. B., Qian, J., Gelman, B. B. & Mazurkiewicz, J. E. Friedreich ataxia: developmental failure of the dorsal root entry zone. J. Neuropathol. Exp. Neurol. 76, 969\u2013977 (2017).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1065_CR73","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/NEN.0b013e31827e5762","volume":"72","author":"AH Koeppen","year":"2013","unstructured":"Koeppen, A. H. & Mazurkiewicz, J. E. Friedreich ataxia: neuropathology revised. J. Neuropathol. Exp. Neurol. 72, 78\u201390 (2013).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1065_CR74","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40478-016-0288-5","volume":"4","author":"AH Koeppen","year":"2016","unstructured":"Koeppen, A. H., Ramirez, R. L., Becker, A. B. & Mazurkiewicz, J. E. Dorsal root ganglia in Friedreich ataxia: satellite cell proliferation and inflammation. Acta Neuropathol. Commun. 4, 46 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"1065_CR75","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/ana.26200","volume":"90","author":"IH Harding","year":"2021","unstructured":"Harding, I. H. et al. Brain structure and degeneration staging in Friedreich ataxia: magnetic resonance imaging volumetrics from the ENIGMA-Ataxia working group. Ann. Neurol. 90, 570\u2013583 (2021).","journal-title":"Ann. Neurol."},{"key":"1065_CR76","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1600-0404.1992.tb04051.x","volume":"85","author":"AC Mart\u00ednez","year":"1992","unstructured":"Mart\u00ednez, A. C. & Anciones, B. Central motor conduction to upper and lower limbs after magnetic stimulation of the brain and peripheral nerve abnormalities in 20 patients with Friedreich\u2019s ataxia. Acta Neurol. Scand. 85, 323\u2013326 (1992).","journal-title":"Acta Neurol. Scand."},{"key":"1065_CR77","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-0404.1983.tb04542.x","volume":"67","author":"G Caruso","year":"1983","unstructured":"Caruso, G. et al. Friedreich\u2019s ataxia: electrophysiological and histological findings. Acta Neurol. Scand. 67, 26\u201340 (1983).","journal-title":"Acta Neurol. Scand."},{"key":"1065_CR78","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.29261","volume":"38","author":"TJR Rezende","year":"2023","unstructured":"Rezende, T. J. R. et al. Progressive spinal cord degeneration in Friedreich\u2019s ataxia: results from ENIGMA-Ataxia. Mov. Disord. 38, 45\u201356 (2023).","journal-title":"Mov. Disord."},{"key":"1065_CR79","doi-asserted-by":"publisher","first-page":"fcac246","DOI":"10.1093\/braincomms\/fcac246","volume":"4","author":"JM Joers","year":"2022","unstructured":"Joers, J. M. et al. Spinal cord magnetic resonance imaging and spectroscopy detect early-stage alterations and disease progression in Friedreich ataxia. Brain Commun. 4, fcac246 (2022).","journal-title":"Brain Commun."},{"key":"1065_CR80","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/ene.13843","volume":"26","author":"TJR Rezende","year":"2019","unstructured":"Rezende, T. J. R. et al. Developmental and neurodegenerative damage in Friedreich\u2019s ataxia. Eur. J. Neurol. 26, 483\u2013489 (2019).","journal-title":"Eur. J. Neurol."},{"key":"1065_CR81","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/mds.27606","volume":"34","author":"PGD Ward","year":"2019","unstructured":"Ward, P. G. D. et al. Longitudinal evaluation of iron concentration and atrophy in the dentate nuclei in Friedreich ataxia. Mov. Disord. 34, 335\u2013343 (2019).","journal-title":"Mov. Disord."},{"key":"1065_CR82","doi-asserted-by":"publisher","first-page":"fcad19","DOI":"10.1093\/braincomms\/fcad196","volume":"5","author":"IM Adanyeguh","year":"2023","unstructured":"Adanyeguh, I. M. et al. Brain MRI detects early-stage alterations and disease progression in Friedreich ataxia. Brain Commun. 5, fcad19 (2023).","journal-title":"Brain Commun."},{"key":"1065_CR83","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","volume":"307","author":"AY Tsou","year":"2011","unstructured":"Tsou, A. Y. et al. Mortality in Friedreich ataxia. J. Neurol. Sci. 307, 46\u201349 (2011).","journal-title":"J. Neurol. Sci."},{"key":"1065_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116396","volume":"10","author":"AH Koeppen","year":"2015","unstructured":"Koeppen, A. H. et al. The pathogenesis of cardiomyopathy in Friedreich ataxia. PLoS ONE 10, e0116396 (2015).","journal-title":"PLoS ONE"},{"key":"1065_CR85","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1089\/scd.2013.0126","volume":"22","author":"A Eigentler","year":"2013","unstructured":"Eigentler, A., Boesch, S., Schneider, R., Dechant, G. & Nat, R. Induced pluripotent stem cells from Friedreich ataxia patients fail to upregulate frataxin during in vitro differentiation to peripheral sensory neurons. Stem Cell Dev. 22, 3271\u20133282 (2013).","journal-title":"Stem Cell Dev."},{"key":"1065_CR86","doi-asserted-by":"publisher","first-page":"fcad007","DOI":"10.1093\/braincomms\/fcad007","volume":"5","author":"C Dionisi","year":"2023","unstructured":"Dionisi, C. et al. Proprioceptors-enriched neuronal cultures from induced pluripotent stem cells from Friedreich ataxia patients show altered transcriptomic and proteomic profiles, abnormal neurite extension, and impaired electrophysiological properties. Brain Commun. 5, fcad007 (2023).","journal-title":"Brain Commun."},{"key":"1065_CR87","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1074\/jbc.RA118.006515","volume":"294","author":"JI Lai","year":"2019","unstructured":"Lai, J. I. et al. Transcriptional profiling of isogenic Friedreich ataxia neurons and effect of an HDAC inhibitor on disease signatures. J. Biol. Chem. 294, 1846\u20131859 (2019).","journal-title":"J. Biol. Chem."},{"key":"1065_CR88","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/13543784.2023.2276758","volume":"32","author":"S Boesch","year":"2023","unstructured":"Boesch, S. & Indelicato, E. Experimental drugs for Friedrich\u2019s ataxia: progress and setbacks in clinical trials. Expert. Opin. Invest. Drugs 32, 967\u2013969 (2023).","journal-title":"Expert. Opin. Invest. Drugs"},{"key":"1065_CR89","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jnc.12219","volume":"126","author":"M Perdomini","year":"2013","unstructured":"Perdomini, M., Hick, A., Puccio, H. & Pook, M. A. Animal and cellular models of Friedreich ataxia. J. Neurochem. 126, 65\u201379 (2013).","journal-title":"J. Neurochem."},{"key":"1065_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001958","volume":"3","author":"M Rai","year":"2008","unstructured":"Rai, M. et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3, e1958 (2008).","journal-title":"PLoS ONE"},{"key":"1065_CR91","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.ymthe.2018.05.006","volume":"26","author":"F Piguet","year":"2018","unstructured":"Piguet, F. et al. Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of Friedreich ataxia. Mol. Ther. 26, 1940\u20131952 (2018).","journal-title":"Mol. Ther."},{"key":"1065_CR92","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nm.3510","volume":"20","author":"M Perdomini","year":"2014","unstructured":"Perdomini, M. et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia. Nat. Med. 20, 542\u2013547 (2014).","journal-title":"Nat. Med."},{"key":"1065_CR93","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1089\/hum.2019.363","volume":"31","author":"CO Salami","year":"2020","unstructured":"Salami, C. O. et al. Stress-induced mouse model of the cardiac manifestations of Friedreich\u2019s ataxia corrected by AAV-mediated gene therapy. Hum. Gene Ther. 31, 819\u2013827 (2020).","journal-title":"Hum. Gene Ther."},{"key":"1065_CR94","doi-asserted-by":"publisher","first-page":"903139","DOI":"10.3389\/fgeed.2022.903139","volume":"4","author":"A Sivakumar","year":"2022","unstructured":"Sivakumar, A. & Cherqui, S. Advantages and limitations of gene therapy and gene editing for Friedreich\u2019s ataxia. Front. Genome Ed. 4, 903139 (2022).","journal-title":"Front. Genome Ed."},{"key":"1065_CR95","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/mt.2015.41","volume":"23","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Excision of expanded GAA repeats alleviates the molecular phenotype of Friedreich\u2019s ataxia. Mol. Ther. 23, 1055\u20131065 (2015).","journal-title":"Mol. Ther."},{"key":"1065_CR96","doi-asserted-by":"publisher","first-page":"101529","DOI":"10.1016\/j.scr.2019.101529","volume":"40","author":"J Li","year":"2019","unstructured":"Li, J. et al. Excision of the expanded GAA repeats corrects cardiomyopathy phenotypes of iPSC-derived Friedreich\u2019s ataxia cardiomyocytes. Stem Cell Res. 40, 101529 (2019).","journal-title":"Stem Cell Res."},{"key":"1065_CR97","doi-asserted-by":"publisher","first-page":"1323491","DOI":"10.3389\/fphar.2024.1323491","volume":"15","author":"P Mishra","year":"2024","unstructured":"Mishra, P. et al. Gene editing improves endoplasmic reticulum-mitochondrial contacts and unfolded protein response in Friedreich\u2019s ataxia iPSC-derived neurons. Front. Pharmacol. 15, 1323491 (2024).","journal-title":"Front. Pharmacol."},{"key":"1065_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17954-3","volume":"11","author":"PG Mazzara","year":"2020","unstructured":"Mazzara, P. G. et al. Frataxin gene editing rescues Friedreich\u2019s ataxia pathology in dorsal root ganglia organoid-derived sensory neurons. Nat. Commun. 11, 4178 (2020).","journal-title":"Nat. Commun."},{"key":"1065_CR99","doi-asserted-by":"publisher","first-page":"eaaj2347","DOI":"10.1126\/scitranslmed.aaj2347","volume":"9","author":"CJ Rocca","year":"2017","unstructured":"Rocca, C. J. et al. Transplantation of wild-type mouse hematopoietic stem and progenitor cells ameliorates deficits in a mouse model of Friedreich\u2019s ataxia. Sci. Transl. Med. 9, eaaj2347 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1065_CR100","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1474-4422(21)00027-2","volume":"20","author":"K Reetz","year":"2021","unstructured":"Reetz, K. et al. Progression characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. Lancet. Neurol. 20, 362\u2013372 (2021).","journal-title":"Lancet. Neurol."},{"key":"1065_CR101","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1212\/01.WNL.0000156802.15466.79","volume":"64","author":"SH Subramony","year":"2005","unstructured":"Subramony, S. H. et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64, 1261\u20131262 (2005).","journal-title":"Neurology"},{"key":"1065_CR102","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-H\u00fcbsch","year":"2006","unstructured":"Schmitz-H\u00fcbsch, T. et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66, 1717\u20131720 (2006).","journal-title":"Neurology"},{"key":"1065_CR103","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1212\/NXG.0000000000000371","volume":"5","author":"C Rummey","year":"2019","unstructured":"Rummey, C. et al. Psychometric properties of the Friedreich ataxia rating scale. Neurol. Genet. 5, 371 (2019).","journal-title":"Neurol. Genet."},{"key":"1065_CR104","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch, D. R. et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study). Ann. Neurol. 89, 212\u2013225 (2021).","journal-title":"Ann. Neurol."},{"key":"1065_CR105","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/acn3.51897","volume":"11","author":"DR Lynch","year":"2024","unstructured":"Lynch, D. R. et al. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. Ann. Clin. Transl. Neurol. 11, 4\u201316 (2024).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1065_CR106","unstructured":"Center for Drug Evaluation and Research. Clinical review(s). Application number: 216718Orig1s000. CDER https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/216718Orig1s000MedR.pdf (2023)."},{"key":"1065_CR107","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14656566.2024.2343782","volume":"25","author":"K Gunther","year":"2024","unstructured":"Gunther, K. & Lynch, D. R. Pharmacotherapeutic strategies for Friedreich ataxia: a review of the available data. Expert. Opin. Pharmacother. 25, 529\u2013539 (2024).","journal-title":"Expert. Opin. Pharmacother."},{"key":"1065_CR108","first-page":"1","volume":"2023","author":"LL Abeysekara","year":"2023","unstructured":"Abeysekara, L. L. et al. A novel feature from instrumented utensils for clinical assessment of Friedreich ataxia. Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. 2023, 1\u20134 (2023).","journal-title":"Annu. Int. Conf. IEEE Eng. Med. Biol. Soc."},{"key":"1065_CR109","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s12311-020-01228-1","volume":"20","author":"LA Corben","year":"2021","unstructured":"Corben, L. A. et al. Developing an instrumented measure of upper limb function in Friedreich ataxia. Cerebellum 20, 430\u2013438 (2021).","journal-title":"Cerebellum"},{"key":"1065_CR110","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41591-022-02159-6","volume":"29","author":"B Kadirvelu","year":"2023","unstructured":"Kadirvelu, B. et al. A wearable motion capture suit and machine learning predict disease progression in Friedreich\u2019s ataxia. Nat. Med. 29, 86\u201394 (2023).","journal-title":"Nat. Med."},{"key":"1065_CR111","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s12311-023-01608-3","volume":"23","author":"AH N\u00e9meth","year":"2024","unstructured":"N\u00e9meth, A. H. et al. Using smartphone sensors for ataxia trials: consensus guidance by the Ataxia Global Initiative Working Group on Digital-Motor Biomarkers. Cerebellum 23, 912\u2013923 (2024).","journal-title":"Cerebellum"},{"key":"1065_CR112","unstructured":"Center for Drug Evaluation and Research. Patient-focused drug development: collecting comprehensive and representative input. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input (2020)."},{"key":"1065_CR113","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ane.12693","volume":"136","author":"G Tai","year":"2017","unstructured":"Tai, G., Corben, L. A., Yiu, E. M. & Delatycki, M. B. A longitudinal study of the SF-36 version 2 in Friedreich ataxia. Acta Neurol. Scand. 136, 41\u201346 (2017).","journal-title":"Acta Neurol. Scand."},{"key":"1065_CR114","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200180","volume":"13","author":"J Seabury","year":"2023","unstructured":"Seabury, J. et al. Friedreich\u2019s ataxia-health index: development and validation of a novel disease-specific patient-reported outcome measure. Neurol. Clin. Pract. 13, e200180 (2023).","journal-title":"Neurol. Clin. Pract."},{"key":"1065_CR115","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200300","volume":"14","author":"J Seabury","year":"2024","unstructured":"Seabury, J. et al. Friedreich Ataxia Caregiver-Reported Health Index: development of a novel, disease-specific caregiver-reported outcome measure. Neurol. Clin. Pract. 14, e200303 (2024).","journal-title":"Neurol. Clin. Pract."},{"key":"1065_CR116","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jacbts.2022.04.005","volume":"7","author":"RM Payne","year":"2022","unstructured":"Payne, R. M. Cardiovascular research in Friedreich ataxia: unmet needs and opportunities. JACC Basic. Transl. Sci. 7, 1267\u20131283 (2022).","journal-title":"JACC Basic. Transl. Sci."},{"key":"1065_CR117","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.111.059477","volume":"125","author":"F Weidemann","year":"2012","unstructured":"Weidemann, F. et al. The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation 125, 1626\u20131634 (2012).","journal-title":"Circulation"},{"key":"1065_CR118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246633","volume":"16","author":"KAG Takazaki","year":"2021","unstructured":"Takazaki, K. A. G. et al. Pre-clinical left ventricular myocardial remodeling in patients with Friedreich\u2019s ataxia: a cardiac MRI study. PLoS ONE 16, e0246633 (2021).","journal-title":"PLoS ONE"},{"key":"1065_CR119","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1007\/s00246-021-02675-1","volume":"42","author":"JA Hutchens","year":"1234","unstructured":"Hutchens, J. A., Johnson, T. R. & Payne, R. M. Myocardial perfusion reserve in children with Friedreich ataxia. Pediatr. Cardiol. 42, 1834\u20131840 (1234).","journal-title":"Pediatr. Cardiol."},{"key":"1065_CR120","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2015.1855","volume":"72","author":"F Pousset","year":"2015","unstructured":"Pousset, F. et al. A 22-year follow-up study of long-term cardiac outcome and predictors of survival in Friedreich ataxia. JAMA Neurol. 72, 1334\u20131341 (2015).","journal-title":"JAMA Neurol."},{"key":"1065_CR121","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/bmj.3.5619.649","volume":"3","author":"RL Hewer","year":"1968","unstructured":"Hewer, R. L. Study of fatal cases of Friedreich\u2019s ataxia. Br. Med. J. 3, 649 (1968).","journal-title":"Br. Med. J."},{"key":"1065_CR122","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pediatrneurol.2021.01.004","volume":"117","author":"E Mejia","year":"2021","unstructured":"Mejia, E. et al. Ectopic burden via Holter monitors in Friedreich\u2019s ataxia. Pediatr. Neurol. 117, 29 (2021).","journal-title":"Pediatr. Neurol."},{"key":"1065_CR123","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijcard.2015.05.074","volume":"194","author":"F Weidemann","year":"2015","unstructured":"Weidemann, F. et al. The cardiomyopathy in Friedreich\u2019s ataxia \u2013 new biomarker for staging cardiac involvement. Int. J. Cardiol. 194, 50\u201357 (2015).","journal-title":"Int. J. Cardiol."},{"key":"1065_CR124","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/21678707.2018.1409109","volume":"6","author":"E Indelicato","year":"2018","unstructured":"Indelicato, E. & B\u00f6sch, S. Emerging therapeutics for the treatment of Friedreich\u2019s ataxia. Expert Opin. Orphan Drugs 6, 57\u201367 (2018).","journal-title":"Expert Opin. Orphan Drugs"},{"key":"1065_CR125","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0140-6736(14)60382-2","volume":"384","author":"V Libri","year":"2014","unstructured":"Libri, V. et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich\u2019s ataxia: an exploratory, open-label, dose-escalation study. Lancet 384, 504\u2013513 (2014).","journal-title":"Lancet"},{"key":"1065_CR126","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3389\/fnins.2019.00386","volume":"13","author":"S Boesch","year":"2019","unstructured":"Boesch, S. & Indelicato, E. Erythropoietin and Friedreich ataxia: time for a reappraisal? Front. Neurosci. 13, 386 (2019).","journal-title":"Front. Neurosci."},{"key":"1065_CR127","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1007\/s13311-019-00764-x","volume":"16","author":"JM Gottesfeld","year":"2019","unstructured":"Gottesfeld, J. M. Molecular mechanisms and therapeutics for the GAA\u00b7TTC expansion disease Friedreich ataxia. Neurotherapeutics 16, 1032\u20131049 (2019).","journal-title":"Neurotherapeutics"},{"key":"1065_CR128","doi-asserted-by":"publisher","first-page":"101179","DOI":"10.1016\/j.omtm.2023.101179","volume":"32","author":"SJ Trantham","year":"2024","unstructured":"Trantham, S. J. et al. Perspectives of the Friedreich ataxia community on gene therapy clinical trials. Mol. Ther. Methods Clin. Dev. 32, 101179 (2024).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1065_CR129","unstructured":"Design Therapeutics. Design Therapeutics reports initial results from phase 1 multiple-ascending dose study of DT-216 for the treatment of Friedreich ataxia. Design Therapeutics https:\/\/investors.designtx.com\/news-releases\/news-release-details\/design-therapeutics-reports-initial-results-phase-1-multiple (2023)."},{"key":"1065_CR130","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/acn3.51971","volume":"11","author":"R Clayton","year":"2024","unstructured":"Clayton, R. et al. Safety, pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI\u20101601) in Friedreich\u2019s ataxia. Ann. Clin. Transl. Neurol. 11, 540 (2024).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1065_CR131","unstructured":"Larimar Therapeutics. Larimar Therapeutics: corporate deck (June 2024). Larimar Therapeutics https:\/\/investors.larimartx.com\/static-files\/6aaf56f2-3c60-4164-a7ea-865cdb0ae356 (2024)."},{"key":"1065_CR132","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/DDDT.S193889","volume":"13","author":"SA Reisman","year":"2019","unstructured":"Reisman, S. A. et al. Pharmacokinetics and pharmacodynamics of the novel NrF2 activator omaveloxolone in primates. Drug. Des. Devel. Ther. 13, 1259\u20131270 (2019).","journal-title":"Drug. Des. Devel. Ther."},{"key":"1065_CR133","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004253","volume":"4","author":"V Paupe","year":"2009","unstructured":"Paupe, V. et al. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS ONE 4, e4253 (2009).","journal-title":"PLoS ONE"},{"key":"1065_CR134","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fncel.2018.00188","volume":"12","author":"R Abeti","year":"2018","unstructured":"Abeti, R., Baccaro, A., Esteras, N. & Giunti, P. Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich\u2019s ataxia models. Front. Cell. Neurosci. 12, 188 (2018).","journal-title":"Front. Cell. Neurosci."},{"key":"1065_CR135","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.29286","volume":"38","author":"DR Lynch","year":"2023","unstructured":"Lynch, D. R. et al. Efficacy of omaveloxolone in Friedreich\u2019s ataxia: delayed-start analysis of the MOXIe extension. Mov. Disord. 38, 313\u2013320 (2023).","journal-title":"Mov. Disord."},{"key":"1065_CR136","doi-asserted-by":"publisher","first-page":"1260977","DOI":"10.3389\/fnins.2023.1260977","volume":"17","author":"C Pane","year":"2023","unstructured":"Pane, C. et al. Rationale and protocol of a double-blind, randomized, placebo-controlled trial to test the efficacy, safety, and tolerability of dimethyl fumarate in Friedreich ataxia (DMF-FA-201). Front. Neurosci. 17, 1260977 (2023).","journal-title":"Front. Neurosci."},{"key":"1065_CR137","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/brain\/awq386","volume":"134","author":"RA Linker","year":"2011","unstructured":"Linker, R. A. et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134, 678\u2013692 (2011).","journal-title":"Brain"},{"key":"1065_CR138","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1093\/hmg\/ddx167","volume":"26","author":"G Hayashi","year":"2017","unstructured":"Hayashi, G. et al. Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans. Hum. Mol. Genet. 26, 2864\u20132873 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"1065_CR139","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217776","volume":"14","author":"M Jasoliya","year":"2019","unstructured":"Jasoliya, M. et al. Dimethyl fumarate dosing in humans increases frataxin expression: a potential therapy for Friedreich\u2019s ataxia. PLoS ONE 14, e0217776 (2019).","journal-title":"PLoS ONE"},{"key":"1065_CR140","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/biom10111551","volume":"10","author":"P La Rosa","year":"2020","unstructured":"La Rosa, P., Petrillo, S., Fiorenza, M. T., Bertini, E. S. & Piemonte, F. Ferroptosis in Friedreich\u2019s ataxia: a metal-induced neurodegenerative disease. Biomolecules 10, 1551 (2020).","journal-title":"Biomolecules"},{"key":"1065_CR141","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.cell.2017.09.044","volume":"171","author":"SE Wenzel","year":"2017","unstructured":"Wenzel, S. E. et al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell 171, 628\u2013641.e26 (2017).","journal-title":"Cell"},{"key":"1065_CR142","unstructured":"Friedreich\u2019s Ataxia Research Alliance. Drug development pipeline. FARA https:\/\/www.curefa.org\/drug-development\/ (2024)."},{"key":"1065_CR143","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/jnc.12322","volume":"126","author":"MH Parkinson","year":"2013","unstructured":"Parkinson, M. H., Schulz, J. B. & Giunti, P. Co-enzyme Q10 and idebenone use in Friedreich\u2019s ataxia. J. Neurochem. 126, 125\u2013141 (2013).","journal-title":"J. Neurochem."},{"key":"1065_CR144","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","volume":"110","author":"N Boddaert","year":"2007","unstructured":"Boddaert, N. et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110, 401\u2013408 (2007).","journal-title":"Blood"},{"key":"1065_CR145","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/ana.24248","volume":"76","author":"M Pandolfo","year":"2014","unstructured":"Pandolfo, M. et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann. Neurol. 76, 509\u2013521 (2014).","journal-title":"Ann. Neurol."},{"key":"1065_CR146","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cmet.2015.01.010","volume":"21","author":"A Martelli","year":"2015","unstructured":"Martelli, A. et al. Iron regulatory protein 1 sustains mitochondrial iron loading and function in frataxin deficiency. Cell Metab. 21, 311\u2013323 (2015).","journal-title":"Cell Metab."},{"key":"1065_CR147","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/mds.29819","volume":"39","author":"M Grander","year":"2024","unstructured":"Grander, M. et al. Genetic determined iron starvation signature in Friedreich\u2019s ataxia. Mov. Disord. 39, 1088\u20131098 (2024).","journal-title":"Mov. Disord."},{"key":"1065_CR148","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/mds.29816","volume":"39","author":"IH Harding","year":"2024","unstructured":"Harding, I. H. et al. Localized changes in dentate nucleus shape and magnetic susceptibility in Friedreich ataxia. Mov. Disord. 39, 1109\u20131118 (2024).","journal-title":"Mov. Disord."},{"key":"1065_CR149","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/mus.26610","volume":"60","author":"M Patel","year":"2019","unstructured":"Patel, M. et al. Open-label pilot study of oral methylprednisolone for the treatment of patients with Friedreich ataxia. Muscle Nerve 60, 571\u2013575 (2019).","journal-title":"Muscle Nerve"},{"key":"1065_CR150","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1007\/s00415-015-7719-2","volume":"262","author":"EM Yiu","year":"2015","unstructured":"Yiu, E. M. et al. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. J. Neurol. 262, 1344\u20131353 (2015).","journal-title":"J. Neurol."},{"key":"1065_CR151","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/acn3.731","volume":"6","author":"DR Lynch","year":"2019","unstructured":"Lynch, D. R. et al. Randomized, double-blind, placebo-controlled study of interferon-\u03b3 1b in Friedreich ataxia. Ann. Clin. Transl. Neurol. 6, 546\u2013553 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1065_CR152","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00415-022-11501-4","volume":"270","author":"DR Lynch","year":"2023","unstructured":"Lynch, D. R. et al. Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia. J. Neurol. 270, 1615\u20131623 (2023).","journal-title":"J. Neurol."},{"key":"1065_CR153","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/brain\/aws309","volume":"136","author":"G Metz","year":"2013","unstructured":"Metz, G. et al. Rating disease progression of Friedreich\u2019s ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database. Brain 136, 259 (2013).","journal-title":"Brain"},{"key":"1065_CR154","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000200034","volume":"8","author":"M Pandolfo","year":"2022","unstructured":"Pandolfo, M. et al. Efficacy and safety of leriglitazone in patients with Friedreich ataxia: a phase 2 double-blind, randomized controlled trial (FRAMES). Neurol. Genet. 8, e200034 (2022).","journal-title":"Neurol. Genet."},{"key":"1065_CR155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010025","volume":"5","author":"D Marmolino","year":"2010","unstructured":"Marmolino, D. et al. PGC-1\u03b1 down-regulation affects the antioxidant response in Friedreich\u2019s ataxia. PLoS ONE 5, e10025 (2010).","journal-title":"PLoS ONE"},{"key":"1065_CR156","doi-asserted-by":"publisher","first-page":"105162","DOI":"10.1016\/j.nbd.2020.105162","volume":"148","author":"L Rodr\u00edguez-Pascau","year":"2021","unstructured":"Rodr\u00edguez-Pascau, L. et al. PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich ataxia. Neurobiol. Dis. 148, 105162 (2021).","journal-title":"Neurobiol. Dis."},{"key":"1065_CR157","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s12311-012-0390-6","volume":"12","author":"CF Chevis","year":"2013","unstructured":"Chevis, C. F. et al. Spinal cord atrophy correlates with disability in Friedreich\u2019s ataxia. Cerebellum 12, 43\u201347 (2013).","journal-title":"Cerebellum"},{"key":"1065_CR158","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1136\/jnnp-2018-318422","volume":"90","author":"I Dogan","year":"2019","unstructured":"Dogan, I. et al. Structural characteristics of the central nervous system in Friedreich ataxia: an in vivo spinal cord and brain MRI study. J. Neurol. Neurosurg. Psychiatry 90, 615\u2013617 (2019).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1065_CR159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269649","volume":"17","author":"N Georgiou-Karistianis","year":"2022","unstructured":"Georgiou-Karistianis, N. et al. A natural history study to track brain and spinal cord changes in individuals with Friedreich\u2019s ataxia: TRACK-FA study protocol. PLoS ONE 17, e0269649 (2022).","journal-title":"PLoS ONE"},{"key":"1065_CR160","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/archneurol.2010.168","volume":"67","author":"DR Lynch","year":"2010","unstructured":"Lynch, D. R., Perlman, S. L. & Meier, T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch. Neurol. 67, 941\u2013947 (2010).","journal-title":"Arch. Neurol."},{"key":"1065_CR161","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/acn3.52057","volume":"11","author":"C Rummey","year":"2024","unstructured":"Rummey, C., Perlman, S., Subramony, S. H., Farmer, J. & Lynch, D. R. Evaluating mFARS in pediatric Friedreich\u2019s ataxia: insights from the FACHILD study. Ann. Clin. Transl. Neurol. 11, 1290\u20131300 (2024).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1065_CR162","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.gaitpost.2018.08.017","volume":"66","author":"B Roche","year":"2018","unstructured":"Roche, B. et al. Test-retest reliability of an instrumented electronic walkway system (GAITRite) for the measurement of spatio-temporal gait parameters in young patients with Friedreich\u2019s ataxia. Gait Posture 66, 45\u201350 (2018).","journal-title":"Gait Posture"},{"key":"1065_CR163","doi-asserted-by":"publisher","first-page":"H346","DOI":"10.1152\/ajpheart.00227.2014","volume":"307","author":"SY Park","year":"2014","unstructured":"Park, S. Y. et al. Cardiac, skeletal, and smooth muscle mitochondrial respiration: are all mitochondria created equal? Am. J. Physiol. Hear. Circ. Physiol. 307, H346 (2014).","journal-title":"Am. J. Physiol. Hear. Circ. Physiol."},{"key":"1065_CR164","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0960-8966(00)00108-5","volume":"10","author":"M Vorgerd","year":"2000","unstructured":"Vorgerd, M. et al. Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscul. Disord. 10, 430\u2013435 (2000).","journal-title":"Neuromuscul. Disord."},{"key":"1065_CR165","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069229","volume":"8","author":"W Nachbauer","year":"2013","unstructured":"Nachbauer, W. et al. Bioenergetics of the calf muscle in Friedreich ataxia patients measured by 31P-MRS before and after treatment with recombinant human erythropoietin. PLoS ONE 8, e69229 (2013).","journal-title":"PLoS ONE"},{"key":"1065_CR166","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1469-8749.2011.03931.x","volume":"53","author":"DA Sival","year":"2011","unstructured":"Sival, D. A. et al. In children with Friedreich ataxia, muscle and ataxia parameters are associated. Dev. Med. Child. Neurol. 53, 529\u2013534 (2011).","journal-title":"Dev. Med. Child. Neurol."},{"key":"1065_CR167","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/NEN.0b013e31825fed76","volume":"71","author":"W Nachbauer","year":"2012","unstructured":"Nachbauer, W. et al. Skeletal muscle involvement in Friedreich ataxia and potential effects of recombinant human erythropoietin administration on muscle regeneration and neovascularization. J. Neuropathol. Exp. Neurol. 71, 708\u2013715 (2012).","journal-title":"J. Neuropathol. Exp. Neurol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01065-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01065-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01065-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T17:36:36Z","timestamp":1743788196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01065-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":167,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01065-y","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"29 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}